Diabetes mellitus: a cardiovascular diseaseNCX-4016 NicOxPossible anti-inflammatory role of COX-2-derived prostaglandins: implications for inflammation researchReverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosisAntiplatelet therapies: platelet GPIIb/IIIa antagonists and beyondAfter 100 years of aspirin, the anticytokine drugs offer a new approach to anti-inflammatory therapyVanoxerine National Institute on Drug AbuseExisulind Cell PathwaysVasoCare. VasogenOverview: Nod2, cause of, or contributor to, Crohn's diseaseLosigamone. Dr Willmar SchwabeParkinson's disease and D1 dopamine receptorsAlanosine (UCSD)Viramidine (Ribapharm)Adenosine A2A receptor agonists as anti-inflammatory agentsDealing with death: HMGB1 as a novel target for cancer therapyMitotane for adrenocortical carcinoma treatmentExperimental therapeutics: targeting the redox Achilles heel of cancerPI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategiesAN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitisBrivaracetam UCBSeletracetam, a small molecule SV2A modulator for the treatment of epilepsyTRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignanciesFAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levelsProgesterone receptor antagonistsTargeted therapies in Waldenström macroglobulinemiaBertilimumab Cambridge Antibody Technology GroupOcrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignanciesPitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczemaN-cadherin as an invasion promoter: a novel target for antitumor therapy?T-cell immune response cDNA 7 in allograft rejection and inflammationMineralocorticoid receptor antagonists and endothelial functionDevelopment of antibiotics and the future of marine microorganisms to stem the tide of antibiotic resistanceThe Th1 immune pathway as a therapeutic target in Crohn's disease.Cyclophilin inhibitors for the treatment of HCV infection.Combination therapy for the treatment of dyslipidemia.Selective androgen receptor modulators: in pursuit of tissue-selective androgens.Microbicides for multidrug-resistant and multitropic HIV-1.Recombinant vaccines for influenza virus.Building an insurance against modern pandemics.
P1433
Q28165843-06CB9E87-EF87-47D5-92C2-0D64FC8D43FDQ28165846-D0508B07-C2B9-44DD-9114-6CB33EC4B74BQ28175941-98B1659B-DF5D-49F6-9EFA-920C464D9210Q28189132-B3B69632-8ACE-4439-9AD4-6C5302661C4BQ28192528-7B463891-8972-4773-993C-6EB74A624DBCQ28196588-DC55B875-B107-4DAE-9BFB-15EDA08D4BAFQ28204803-98791C73-1583-41EE-AEAC-C0C06F937653Q28204806-7E4A78BC-E4BA-4357-BD42-216CD8FFB4EFQ28206566-FF96EA84-7F9D-4635-BB9B-8B737C3E37D1Q28206606-1E4A02DB-BFB8-4679-9522-49285B777585Q28206927-158C2A31-547D-4E5D-96B1-ADD934699428Q28213980-AA4CCF72-F036-498A-835F-02D7770569F2Q28213989-3D56CCD0-1914-46B0-BF7A-043DBD03F161Q28217170-86C74866-317C-4062-B596-19095342E38BQ28242079-056CAE7E-AB81-489E-8561-93794EC38774Q28242457-8CDE19D5-494F-434D-911E-AD180DEFE631Q28251224-29C7DF7B-2857-4490-ACAF-58C5ED159AC3Q28259928-70339083-763F-4035-8C82-35AB0709A5CCQ28263112-E5FCA729-658F-4AA9-80BA-34B3B09D7651Q28263122-72BD5EB7-3A12-4F12-8A5F-9EFB30583509Q28263663-FDD2FFD8-2D56-4CA0-9ED5-1AD07D664DE6Q28264067-45A4AB3E-FE9F-4EB8-AAAE-4E31561DEEE8Q28265937-E1A8CD08-DB0D-40E4-AA5A-C96A8D716D7DQ28269212-CE05892C-F4E3-4D58-83AD-05579F485E1BQ28272578-141C12E8-3AFC-486D-B88A-58A9ACEF5140Q28282343-F714F110-791D-4FCE-A6AA-610D5D5B6544Q28295955-633F3F20-A505-4C03-A5CB-C2A75B1ECD86Q28298623-6E788B8D-5F8B-475B-8D6C-6BEDBAAAE1FFQ28301047-647F24AE-BC3A-4342-9E79-8C6851E6D9D9Q28302289-3BA06C01-DFA7-4CCA-ABC6-19A06135CBC5Q28303591-347638C2-0428-4DAC-8037-4CB547CF2559Q28645984-DFDA17AB-B205-4216-947B-5523F49A5C4BQ28828265-5538E965-3B80-46DF-9F74-D91301F0D65FQ30312066-E1505968-CA52-432E-9E4E-B3546A47010EQ30318599-A56096D5-BEC9-47A2-B154-6201EB59998AQ30341247-3CBDA3C9-E0DB-42E1-B412-D4BB90841A9BQ30357822-382BF8D0-AAD4-45F7-87DA-0742358F2FF2Q30367564-4CFD161D-E53F-4071-A143-94F9A99C9909Q30371062-FD08B08D-A623-4C17-9EF1-0F4ABF129708Q30385005-BB6EB17F-DCA7-49A9-8A3E-17B15DA9224E
P1433
description
journal
@en
publikation
@de
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Thomson Reuters
@nl
مجلة
@ar
वैज्ञानिक पत्रिका
@hi
name
Current Opinion in Investigational Drugs
@de
Current Opinion in Investigational Drugs
@en
Current Opinion in Investigational Drugs
@es
Current Opinion in Investigational Drugs
@it
Current Opinion in Investigational Drugs
@nl
label
Current Opinion in Investigational Drugs
@de
Current Opinion in Investigational Drugs
@en
Current Opinion in Investigational Drugs
@es
Current Opinion in Investigational Drugs
@it
Current Opinion in Investigational Drugs
@nl
prefLabel
Current Opinion in Investigational Drugs
@de
Current Opinion in Investigational Drugs
@en
Current Opinion in Investigational Drugs
@es
Current Opinion in Investigational Drugs
@it
Current Opinion in Investigational Drugs
@nl
P1055
P1058
P1156
P123
P1277
P1476
Current Opinion in Investigational Drugs
@und
P236
P407
P571
2000-01-01T00:00:00Z
P582
2010-01-01T00:00:00Z